Related references
Note: Only part of the references are listed.Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay
Timo Deutschbein et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome
Maria Fleseriu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
Annamaria Colao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate
Jens Heyn et al.
PITUITARY (2012)
Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial
David A. Calhoun et al.
CIRCULATION (2011)
Measurement of Urinary Free Cortisol by Current Immunoassays: Need for Sex-dependent Reference Ranges to Define Hypercortisolism
T. Deutschbein et al.
HORMONE AND METABOLIC RESEARCH (2011)
Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome
Peter Kamenicky et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Mortality and Morbidity in Cushing's Disease over 50 Years in Stoke-on-Trent, UK: Audit and Meta-Analysis of Literature
R. N. Clayton et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Management of Cushing disease
Nicholas A. Tritos et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain
J. K. Belanoff et al.
DIABETES OBESITY & METABOLISM (2010)
Cabergoline monotherapy in the long-term treatment of Cushing's disease
Ariane Godbout et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases
H. Bode et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2010)
Aldosterone Synthase Inhibition With LCI699 A Proof-of-Concept Study in Patients With Primary Aldosteronism
Laurence Amar et al.
HYPERTENSION (2010)
Role of the PPAR-gamma System in Normal and Tumoral Pituitary Corticotropic Cells and Adrenal Cells
Massimo Mannelli et al.
NEUROENDOCRINOLOGY (2010)
Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease
Richard A. Feelders et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease
Lucio Vilar et al.
PITUITARY (2010)
Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease
Kimberly Cukier et al.
CLINICAL ENDOCRINOLOGY (2009)
Merits and pitfalls of mifepristone in Cushing's syndrome
F. Castinetti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Drugs in the medical treatment of Cushing's syndrome
David E. Schteingart
EXPERT OPINION ON EMERGING DRUGS (2009)
Differential Ligand-Mediated Pituitary Somatostatin Receptor Subtype Signaling: Implications for Corticotroph Tumor Therapy
Anat Ben-Shlomo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial
M. Boscaro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery
Rosario Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease
F. Castinetti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Late recurrences of Cushing's disease after initial successful transsphenoidal surgery
Chirag G. Patil et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Treatment of adrenocorticotropin-dependent Cushing's syndrome: A consensus statement
B. M. K. Biller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Mifepristone (RU 486) in Cushing's syndrome
Sarah Johanssen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Long-term treatment of central Cushing's syndrome with rosiglitazone
M. Morcos et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2007)
Dopamine agonists and the risk of cardiac-valve regurgitation
Rene Schade et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Corticotroph tumor progression after adrenalectomy in Cushing's disease:: A reappraisal of Nelson's syndrome
Guillaume Assie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas
Dalia L. Batista et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
PPAR-γ expression in pituitary tumours and the functional activity of the glitazones:: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-γ receptor
Michelle N. Emery et al.
CLINICAL ENDOCRINOLOGY (2006)
Long term control of hypercortisolism with fluconazole:: case report and in vitro studies
M Riedl et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease
FP Giraldi et al.
CLINICAL ENDOCRINOLOGY (2006)
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells
J van der Hoek et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
Regulation of ghrelin secretion by somatostatin analogs in rats
AP Silva et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5
LJ Hofland et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease
D Suri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease
JE Greening et al.
HORMONE RESEARCH (2005)
Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease
B Ambrosi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Dopamine receptor expression and function in corticotroph pituitary tumors
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Quality of life after laparoscopic bilateral adrenalectomy for Cushing's disease
MT Hawn et al.
SURGERY (2002)
Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
AP Heaney et al.
NATURE MEDICINE (2002)
Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells
MZ Strowski et al.
NEUROENDOCRINOLOGY (2002)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)
JW Chu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Dopamine D2 receptor gene expression in human adenohypophysial adenomas
L Stefaneanu et al.
ENDOCRINE (2001)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)